Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Late phase II study of selexipag in intermittent claudication due to arteriosclerosis obliterans
jRCT2080223273Phase 2Completed
- Sponsor
- Nippon Shinyaku
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in intermittent claudication (IC) and arteriosclerosis obliterans comparing Selexipag (NS-304) with Placebo (2 arms). Started Jul 2016; status: completed.
02
Drugs
selexipag
03
Conditions
intermittent claudication (IC)arteriosclerosis obliterans
Beyond the preview
Go deeper on jRCT2080223273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223273.